 Doxorubicin
"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1997 | 3 | 1 | 4 | | 1998 | 1 | 4 | 5 | | 1999 | 1 | 2 | 3 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 7 | 8 | | 2002 | 1 | 3 | 4 | | 2003 | 0 | 2 | 2 | | 2004 | 2 | 1 | 3 | | 2006 | 2 | 5 | 7 | | 2007 | 2 | 5 | 7 | | 2008 | 0 | 6 | 6 | | 2009 | 4 | 6 | 10 | | 2010 | 0 | 5 | 5 | | 2011 | 2 | 6 | 8 | | 2012 | 2 | 6 | 8 | | 2013 | 2 | 6 | 8 | | 2014 | 2 | 8 | 10 | | 2015 | 2 | 5 | 7 | | 2016 | 5 | 5 | 10 | | 2017 | 2 | 9 | 11 | | 2018 | 0 | 7 | 7 | | 2019 | 1 | 11 | 12 | | 2020 | 2 | 8 | 10 | | 2021 | 4 | 9 | 13 | | 2022 | 1 | 6 | 7 | | 2023 | 5 | 9 | 14 | | 2024 | 5 | 7 | 12 | | 2025 | 5 | 6 | 11 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Chen XL, Tharp KM, Ojalill M, Ozmadenci D, Boyer A, Haanen TJ, Lawson C, Lee HJ, Xia M, Tahon E, Zhang Y, Minor C, Khan SU, Anderson CC, Nemkov T, Rose M, Estrada MV, Molinolo AA, Warren E, Penalosa P, Eskander RN, McHale MT, Wang SE, Connolly DC, Fisch KM, Stupack DG, Schlaepfer DD. FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages. Cell Rep. 2026 Mar 24; 45(3):117009.
-
Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A. Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R. Haematologica. 2026 Apr 01; 111(4):1389-1395.
-
Venkatasubramanian R, Mahoney SA, Hutton DA, VanDongen NS, Brunt VE, Greenberg NT, Longtine AG, Brandt L, Beyer AM, Melov S, Rossman MJ, Seals DR, Clayton ZS. Cellular senescence mediates doxorubicin chemotherapy-induced vascular endothelial dysfunction: translational evidence of prevention with senolytic treatment. Am J Physiol Heart Circ Physiol. 2025 Dec 01; 329(6):H1672-H1683.
-
Clayton ZS, Nguyen BL, Venkatasubramanian R, Kabos P. Exercise to Mitigate Premature Vascular Aging After Doxorubicin Breast Cancer Therapy. Exerc Sport Sci Rev. 2025 Oct 01; 53(4):187-194.
-
Montalvo RN, Nguyen BL, Doerr V, Dowllah IM, Wendler CC, Baumfalk DR, Babuschak JC, Krueger RW, Smuder AJ. Sex Differences in Response to Acute Doxorubicin Cardiorespiratory Muscle Dysfunction and Preconditioning Exercise. Med Sci Sports Exerc. 2026 Jan 01; 58(1):47-59.
-
Guo Z, Ataran A, Ma P, Yu W, Hajirezaei H, Valenzuela Ripoll C, Pedersen LN, Rashidi O, Chan MM, Shen M, Kelley S, Sargazi A, Ozcan M, Lotfinaghsh A, Cho Y, Diab A, Grogan F, Klaas A, Pompian A, Imam A, Lodhi R, Zelleke AB, Kovacs A, Margulies KB, Szymanski J, Sardiello M, Razani B, Asnani A, Kopecky BJ, Signore PE, Yi BA, Basson CT, Ravichandran KS, Prabhu SD, Bergom C, Schilling JD, Lavine KJ, Javaheri A. Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. Circulation. 2025 Sep 09; 152(10):661-681.
-
Mondello P, Negaard B, Feldman AL, Link BK, Casulo C, Chihara D, Russler-Germain D, Romancik J, Gribbin C, Haddadi S, Mou E, Micallef IN, Johnston PB, Novak J, Wang Y, King RL, Novak AJ, Habermann TM, Martin P, Kahl B, Nowakowski GS, Nastoupil LJ, Cerhan JR, Flowers CR, Lossos IS, Burack RW, Maurer MJ, Ansell SM. Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts. Blood Cancer J. 2025 Aug 08; 15(1):134.
-
Venkatasubramanian R, Darrah MA, Mahoney SA, Hutton DA, Maurer GS, Ludwig KR, Van Dongen NS, Greenberg NT, Longtine AG, Brunt VE, Singh P, Galligan JJ, Trujillo MN, Kapahi P, Melov S, Rossman MJ, Seals DR, Clayton ZS. Cellular Senescence Mediates Doxorubicin Chemotherapy-Induced Aortic Stiffening: Role of Glycation Stress. Hypertension. 2025 Oct; 82(10):1767-1777.
-
Wilky BA, Julian KA, Maleddu A, Mailhot AC, Cartwright CR, Gao D, Moreno Tellez C, Kemp LE, Therrien NR, Chaudhry SS, Rytlewski JD, Brockman QR, Davila E, Elias AD. A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas. Clin Cancer Res. 2025 Jul 15; 31(14):2945-2956.
-
Li Y, Jacques S, Gaikwad H, Nebbia M, Banda NK, Holers VM, Tomlinson SA, Scheinman RI, Monte A, Saba L, Lasda E, Hasselberth J, Busquet N, Zelek WM, Moghimi SM, Simberg D. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Sci Adv. 2025 Jul 11; 11(28):eadw1731.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|